Kintara Therapeutics Inc

NASDAQ:KTRA  
1.39
+0.02 (+1.84%)
Products

Kintara Therapeutics Reports 10 Months Progression-Free Survival In Newly-Diagnosed MGMT-Unmethylated GBM From Ongoing MD Anderson Cancer Center Phase 2 Study

Published: 11/19/2020 13:15 GMT
Kintara Therapeutics Inc (KTRA) - Kintara Therapeutics Reports 10 Months Progression-free Survival in Newly-diagnosed Mgmt-unmethylated Gbm From Ongoing Md Anderson Cancer Center Phase 2 Study.
Kintara Therapeutics - Myelosuppression is Most Common Adverse Event With Val-083 in Both Recurrent Gbm and Adjuvant Treatment Setting.
Kintara Therapeutics - in 30 Mg/m(2)/day Starting Dose Cohort 3 Subjects Experienced Serious Adverse Event Possibly Related to Val-083 in Recurrent Group.
Kintara Therapeutics Inc - in 30 Mg/m(2)/day Starting Dose Cohort One Patient Has Experienced a Possibly Drug-related Sae in Adjuvant Group.
Kintara - in Newly-diagnosed Treatment Setting, Promising Median Progression-free Survival of 10.0 Months With Val-083 Versus Tmz Historical Data.